Arvinas (ARVN) Profit After Tax (2017 - 2026)
Arvinas (ARVN) posted quarterly Profit After Tax of -$57.6 million for Q1 2026, down 169.06% year-over-year from $83.4 million in Q1 2025, and up 14.79% quarter-over-quarter from -$67.6 million in Q4 2025.
Analysis
Arvinas (ARVN) Profit After Tax (2017 - 2026) Analysis & Trends
Arvinas' Profit After Tax history runs 10 years deep, the most recent figure standing at -$57.6 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 169.06% year-over-year to -$57.6 million; the TTM figure through Mar 2026 stood at -$221.1 million (down 488.03% YoY), while the FY2025 annual figure was -$80.6 million, up 59.48% from the prior year.
- Profit After Tax for Q1 2026 stood at -$57.6 million, up from -$67.6 million in the prior quarter.
- The five-year high for Profit After Tax was $83.4 million in Q1 2025, with the low at -$138.7 million in Q4 2023.
- The 5-year median for Profit After Tax is -$62.7 million (2022), against an average of -$55.0 million.
- The sharpest annual moves came in 2025 and 2026: Profit After Tax jumped 220.17% in 2025, then slumped 169.06% in 2026.
- Arvinas' Profit After Tax stood at -$62.7 million in 2022, then sank by 121.21% to -$138.7 million in 2023, then soared by 67.48% to -$45.1 million in 2024, then tumbled by 49.89% to -$67.6 million in 2025, then rose by 14.79% to -$57.6 million in 2026.
- Business Quant data shows ARVN's Profit After Tax at -$57.6 million in Q1 2026, -$67.6 million in Q4 2025, and -$34.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Arvinas | 604.91 Mn | 37.01 Mn | - | 169.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 169.40 Mn |
| Mar 31, 2026 | -59.20 Mn |
| Dec 31, 2025 | -67.40 Mn |
| Sep 30, 2025 | -35.10 Mn |
| Jun 30, 2025 | -61.70 Mn |
| Mar 31, 2025 | 83.40 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -35.20 Mn |
| Mar 31, 2024 | -70.70 Mn |
| Dec 31, 2023 | -154.80 Mn |
| Sep 30, 2023 | -64.00 Mn |
| Jun 30, 2023 | -66.60 Mn |
| Mar 31, 2023 | -81.90 Mn |
| Dec 31, 2022 | -77.20 Mn |
| Sep 30, 2022 | -69.00 Mn |
| Jun 30, 2022 | -73.30 Mn |
| Mar 31, 2022 | -77.50 Mn |
| Dec 31, 2021 | -57.00 Mn |
| Sep 30, 2021 | -46.90 Mn |